Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
You may also be interested in...
Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.